• Teva Page Title

Korporativne novice

Opomba: novice so v angleškem jeziku, povezave vodijo na korporativno stran podjetja Teva.

20.04.2017

Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol

First and Only Generic Fluticasone Propionate and Salmeterol (ICS/LABA) Inhaler Available in the U.S. JERUSALEM--(BUSINESS WIRE)--Apr. 20, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced the simultaneous launch of AirDuo™ RespiClick® (fluticasone propionate and salmeterol) inhalation powder and its authorized generic for the treatment of asthma in patients aged 12 years and older who are uncontrolled on an inhaled corticosteroid (ICS) or whose disease severity clearly warrants the use of an ICS/long-acting beta2-adrenergic agonist (LABA) combination. AirDuo™ RespiClick® and its ...
19.04.2017

Teva Showcases CNS Portfolio at 69th Annual Meeting of the American Academy of Neurology

Data to be presented spans central nervous system disorders, including tardive dyskinesia, multiple sclerosis, Huntington’s disease, and migraine JERUSALEM--(BUSINESS WIRE)--Apr. 19, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced data for five of the Company’s innovative therapies for central nervous system (CNS) disorders will be presented at the 69th Annual Meeting of the American Academy of Neurology (AAN) in Boston, MA from April 22-28, 2017. The accepted abstracts include data from Teva’s approved and pipeline products, with three platform and 16 poster presentations. Dat...
06.04.2017

Teva to Report First Quarter 2017 Financial Results on May 11, 2017

JERUSALEM--(BUSINESS WIRE)--Apr. 6, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its first quarter 2017 financial results on Thursday, May 11, 2017 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its first quarter 2017 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States 1-866-869-2321; Canada 1-866-766-8269 or International +4...
03.04.2017

Teva Announces FDA Approval of AUSTEDO™ (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease

Approval represents the first new treatment option for chorea associated with Huntington’s disease in nearly a decade JERUSALEM--(BUSINESS WIRE)--Apr. 3, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO™ (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease (HD). Previously referred to by the developmental name SD-809, AUSTEDOTM is the first deuterated product approved by the FDA and only the second product approved in HD. The product was previously granted Orphan Drug Designation by the ...
16.03.2017

Teva Announces Launch of Authorized Generic of Minastrin® 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) in the United States

JERUSALEM--(BUSINESS WIRE)--Mar. 16, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of the Authorized Generic of Minastrin® 24 Fe1 (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) 1 mg/20 mcg in the U.S. The Authorized Generic of Minastrin® 24 Fe is an estrogen/progestin combined oral contraceptive indicated for use by women to prevent pregnancy. This Authorized Generic of Minastrin® 24 Fe adds to Teva’s existing portfolio of more than 50 oral contraceptives. In the U.S., one of every two oral contraceptive prescriptions is fille...
13.03.2017

Teva to Present at the Barclays Global Annual Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--Mar. 13, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Barclays Global Healthcare Conference in Miami, Florida.   When: Wednesday, March 15, 2017 at 9:00 AM ET   Who: Eyal Desheh, Gr...
06.03.2017

Teva to Present at the Cowen & Company 37th Annual Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--Mar. 6, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Cowen & Company 37th Annual Healthcare Conference in Boston, MA. When:   Wednesday, March 8, 2017 at 9:20 AM ET   Who: Marcelo Bigal, M.D. Ph.D., SVP, Head of Global Specialty Development, ...
01.03.2017

Teva Announces Launch of Generic Pristiq® in the United States

JERUSALEM--(BUSINESS WIRE)--Mar. 1, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of generic Pristiq®1 (desvenlafaxine) extended-release tablets, 25, 50 and 100 mg, in the U.S. Desvenlafaxine extended-release tablets are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder. Desvenlafaxine extended-release tablets further enhance Teva’s portfolio of antidepressant products. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and hol...
28.02.2017

Teva Announces Priority Review Granted by FDA for SD-809 for Treatment of Tardive Dyskinesia

JERUSALEM--(BUSINESS WIRE)--Feb. 28, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for SD-809 (deutetrabenazine) for the treatment of tardive dyskinesia (TD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 30, 2017. “Teva is committed to advancing new therapeutic options for patients with neurological and movement disorders. There remains a significant unmet medical need in tardive dyskinesia,” said Michael Hayden, M.D., Ph.D., Presi...
15.02.2017

Teva Files 2016 Annual Report on Form 20-F

JERUSALEM--(BUSINESS WIRE)--Feb. 15, 2017-- In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has filed its 2016 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company’s website at www.tevapharm.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company’s complete audited financial statements, free of charge. Requests can be made by contacting Teva ...